Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

Public Health, Biostatistics, Cost-effectiveness Analysis +15

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Medicine, Oncology, Pharmacology +13

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

The Annals of Statistics · 1988 · 5K citations · Full text

Public Health, Biostatistics, Risk Analysis +15

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Daniel Betticher, Shu‐Fang Hsu Schmitz, Martin Tötsch et al. · Journal of Clinical Oncology · 2003 · 455 citations

Medicine, Oncology, Pharmacology +17